Results 271 to 280 of about 11,748,393 (397)

Digital Activity Markers in Chronic Inflammatory Demyelinating Polyneuropathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the utility of smartwatch and smartphone‐based activity metrics for assessing disease severity and quality of life in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Methods In the electronic monitoring of disease activity in patients with CIDP (EMDA‐CIDP) trial, we performed a prospective ...
Lars Masanneck   +15 more
wiley   +1 more source

Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti‐CD20 therapy on clinical and sub‐clinical outcomes in multiple sclerosis. Methods Clinical information was collected prospectively on Research Electronic Data Capture.
Nabil K. El Ayoubi   +6 more
wiley   +1 more source

Personalized medicine: An era of dosage form development

open access: yesJournal of Advanced Pharmaceutical Technology & Research, 2017
Upendra Nagaich
doaj   +1 more source

New Oral Dosage Form for Elderly Patients: Preparation and Characterization of Silk Fibroin Gel.

open access: bronze, 1995
Takehisa Hanawa   +5 more
openalex   +2 more sources

Safe to crush? A pilot study into solid dosage form modification in aged care

open access: yesAustralasian Journal on Ageing, 2014
Nicole Mercovich, G. Kyle, M. Naunton
semanticscholar   +1 more source

Efgartigimod Combined With Steroid Treatment for HAM/TSP: A Case Report

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive neurological disorder with limited treatment options. We report a 54‐year‐old female with decade‐long, progressive HAM/TSP, previously refractory to rituximab, who experienced worsening spastic paraparesis and neurogenic bladder dysfunction.
Jiahui Zeng   +5 more
wiley   +1 more source

Patient Acceptability and Preferences for Solid Oral Dosage Form Drug Product Attributes: A Scoping Review. [PDF]

open access: yesPatient Prefer Adherence
Hauber B   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy